Optimising surveillance and outcomes in SLE

The overall purpose of this project is to contribute to optimization of the use of current therapies in SLE, propose new therapies, increase awareness regarding non-pharmacological interventions such as smoking cessation, and develop tools for better surveillance of the disease and for prediction of disease course, response to therapies, and long-term outcome.

Below you may find some selected publications within this project.

Selected publications

  1. Louis Sam Titus ASC, Tan Y, Tran P, Lindblom J, Ivbievbiokun M, Xu Y, Zheng J, Parodis I, Cai Q, Chang A, Chen SH, Zhao M, Mohan C. Molecular architecture of proliferative lupus nephritis as elucidated using 50-plex imaging mass cytometry proteomics. Clin Immunol. 2023 Sep;254:109713.

  2. Parodis I, Lindblom J, Cetrez N, Palazzo L, Ala H, Houssiau FA, Sjöwall C, Rovin BH. Effect of belimumab on preventing de novo renal lupus flares. Kidney International Reports. 2023 Jul.

  3. Palazzo L, Lindblom J, Çetrez N, Ala H, Parodis I. Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab. Rheumatology (Oxford). 2023 May 25:kead249.

  4. Gomez A, Jägerback S, Sjöwall C, Parodis I. Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials. Rheumatology (Oxford). 2023 May 25:kead253.

  5. Lindblom J, Toro-Domínguez D, Carnero-Montoro E, Beretta L, Borghi MO, Castillo J, Enman Y; PRECISESADS Clinical Consortium; Mohan C, Alarcón-Riquelme ME, Barturen G, Parodis I. Distinct gene dysregulation patterns herald precision medicine potentiality in systemic lupus erythematosus. J Autoimmun. 2023 Apr;136:103025.

  6. Parodis I, Gomez A, Lindblom J, Chow JW, Sjöwall C, Sciascia S, Gatto M. B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab. Int J Mol Sci. 2022 Nov 11;23(22):13941.

  7. Parodis I, Gomez A, Chow JW, Borg A, Lindblom J, Gatto M. Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab. Front Immunol. 2022 Apr 4;13:796508.

  8. Chalmers SA, Ayilam Ramachandran R, Garcia SJ, Der E, Herlitz L, Ampudia J, Chu D, Jordan N, Zhang T, Parodis I, Gunnarsson I, Ding H, Shen N, Petri M, Mok CC, Saxena R, Polu KR, Connelly S, Ng CT, Mohan C, Putterman C. The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses. J Clin Invest. 2022 Jan 4;132(1):e147334.

  9. Parodis I, Vital EM, Hassan SU, Jönsen A, Bengtsson AA, Eriksson P, Leonard D, Gunnarsson I, Rönnblom L, Sjöwall C. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021 Sep 1;60(9):4348-4354.

  10. Parodis I, Adamichou C, Aydin S, Gomez A, Demoulin N, Weinmann-Menke J, Houssiau FA, Tamirou F. Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford). 2020 Nov 1;59(11):3424-3434.

  11. Parodis I, Gokaraju S, Zickert A, Vanarsa K, Zhang T, Habazi D, Botto J, Serdoura Alves C, Giannopoulos P, Larsson A, Svenungsson E, Gunnarsson I, Mohan C. ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus. Rheumatology (Oxford). 2020 Sep 1;59(9):2237-2249.

  12. Parodis I, Åkerström E, Sjöwall C, Sohrabian A, Jönsen A, Gomez A, Frodlund M, Zickert A, Bengtsson AA, Rönnelid J, Gunnarsson I. Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus. International Journal of Molecular Sciences. 2020 May 14;21(10).

  13. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7.

  14. Parodis I, Ding H, Zickert A, Cosson G, Fathima M, Grönwall C, Mohan C, Gunnarsson I. Serum Axl predicts histology-based response to induction therapy and long-term renal outcome in lupus nephritis. PLoS One. 2019 Feb 11;14(2):e0212068.

  15. Parodis I, Ding H, Zickert A, Arnaud L, Larsson A, Svenungsson E, Mohan C, Gunnarsson I. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. Scand J Rheumatol. 2017 Jul;46(4):263-272.

  16. Parodis I, Zickert A, Sundelin B, Axelsson M, Gerhardsson J, Svenungsson E, Malmström V, Gunnarsson I. Evaluation of B lymphocyte stimulator and a proliferation inducing ligand as candidate biomarkers in lupus nephritis based on clinical and histopathological outcome following induction therapy. Lupus Sci Med. 2015 Jan 22;2(1):e000061.

Donate to our research